| Q27490518 | A Turn-like Structure "KKPE" Segment Mediates the Specific Binding of Viral Protein A27 to Heparin and Heparan Sulfate on Cell Surfaces |
| Q40060063 | A comparative review of viral entry and attachment during large and giant dsDNA virus infections. |
| Q36747975 | A conserved sequence within the H2 subunit of the vaccinia virus entry/fusion complex is important for interaction with the A28 subunit and infectivity |
| Q57160786 | A proteomic atlas of the African swine fever virus particle |
| Q31051453 | A putative cell surface receptor for white spot syndrome virus is a member of a transporter superfamily |
| Q27314496 | African Swine Fever Virus Undergoes Outer Envelope Disruption, Capsid Disassembly and Inner Envelope Fusion before Core Release from Multivesicular Endosomes |
| Q52880891 | Amsacta moorei entomopoxvirus encodes a functional heparin-binding glycosyltransferase (AMV248). |
| Q36559826 | Analysis of viral membranes formed in cells infected by a vaccinia virus L2-deletion mutant suggests their origin from the endoplasmic reticulum |
| Q39167579 | Antibody Recognition of Immunodominant Vaccinia Virus Envelope Proteins |
| Q35744848 | Antiviral activity of the EB peptide against zoonotic poxviruses |
| Q37359610 | Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry |
| Q35857238 | Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex |
| Q36911682 | Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens. |
| Q41808554 | Baculovirus per os infectivity factors form a complex on the surface of occlusion-derived virus. |
| Q37452527 | Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses |
| Q42152766 | Characterization of novel components of the baculovirus per os infectivity factor complex |
| Q34976944 | Crystal structure of vaccinia viral A27 protein reveals a novel structure critical for its function and complex formation with A26 protein |
| Q38704031 | Deletion of the Vaccinia Virus I2 Protein Interrupts Virion Morphogenesis, Leading to Retention of the Scaffold Protein and Mislocalization of Membrane-Associated Entry Proteins |
| Q35941208 | Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized Screening |
| Q30488301 | Disulfide bond formation at the C termini of vaccinia virus A26 and A27 proteins does not require viral redox enzymes and suppresses glycosaminoglycan-mediated cell fusion |
| Q28477161 | Drosophila S2 cells are non-permissive for vaccinia virus DNA replication following entry via low pH-dependent endocytosis and early transcription |
| Q34233115 | Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene |
| Q90051677 | Experimental evolution to isolate vaccinia virus adaptive G9 mutants that overcome membrane fusion inhibition by vaccinia A56/K2 protein complex |
| Q37099872 | Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion |
| Q35383164 | Expression profiling of the intermediate and late stages of poxvirus replication |
| Q39905666 | Functional characterization of the vaccinia virus I5 protein |
| Q36550897 | In a nutshell: structure and assembly of the vaccinia virion |
| Q42143723 | Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide |
| Q42212627 | Initial characterization of vaccinia virus B4 suggests a role in virus spread |
| Q34273718 | Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain |
| Q36086790 | Integrin β1 mediates vaccinia virus entry through activation of PI3K/Akt signaling |
| Q34778139 | Interaction between the G3 and L5 proteins of the vaccinia virus entry-fusion complex |
| Q33664851 | Kinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus |
| Q35260919 | Lipid membranes in poxvirus replication |
| Q38899115 | Membrane fusion during poxvirus entry |
| Q90051687 | Mutations Near the N-Terminus of the Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex |
| Q35274869 | Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway |
| Q91723814 | Nanoscale polarization of the entry fusion complex of vaccinia virus drives efficient fusion |
| Q36315941 | Orthopoxvirus species and strain differences in cell entry |
| Q37173398 | Orthopoxvirus targets for the development of new antiviral agents. |
| Q38650037 | Per os infectivity factors: a complicated and evolutionarily conserved entry machinery of baculovirus |
| Q27684713 | Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein |
| Q30809790 | Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. |
| Q27002455 | Poxvirus cell entry: how many proteins does it take? |
| Q37640977 | Poxvirus proteomics and virus-host protein interactions |
| Q45411811 | Protein composition of the vaccinia virus mature virion |
| Q36498147 | Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine |
| Q36103310 | Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells |
| Q39545996 | Role of sulfatide in vaccinia virus infection. |
| Q36655196 | Role of the vaccinia virus O3 protein in cell entry can be fulfilled by its Sequence flexible transmembrane domain |
| Q30978284 | Salmon Gill Poxvirus, the Deepest Representative of the Chordopoxvirinae |
| Q35689728 | Sequence-divergent chordopoxvirus homologs of the o3 protein maintain functional interactions with components of the vaccinia virus entry-fusion complex |
| Q35784794 | Sequence-independent targeting of transmembrane proteins synthesized within vaccinia virus factories to nascent viral membranes |
| Q34780607 | Smallpox vaccines: targets of protective immunity |
| Q92409616 | Species-Specific Conservation of Linear Antigenic Sites on Vaccinia Virus A27 Protein Homologs of Orthopoxviruses |
| Q27647102 | Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein |
| Q37902736 | Structure and working of viral fusion machinery |
| Q59127072 | The 2.1 Å structure of protein F9 and its comparison to L1, two components of the conserved poxvirus entry-fusion complex |
| Q40378452 | The African swine fever virus virion membrane protein pE248R is required for virus infectivity and an early postentry event |
| Q59350375 | The Ectodomain of the Vaccinia Virus Glycoprotein A34 is Required for Cell Binding by Extracellular Virions and Contains a Large Region Capable of Interaction with the Glycoprotein B5 |
| Q39914349 | The Large Marseillevirus Explores Different Entry Pathways by Forming Giant Infectious Vesicles |
| Q36878858 | The Vaccinia Virus H3 Envelope Protein, a Major Target of Neutralizing Antibodies, Exhibits a Glycosyltransferase Fold and Binds UDP-Glucose |
| Q35024119 | The envelope G3L protein is essential for entry of vaccinia virus into host cells |
| Q34109783 | The membrane fusion step of vaccinia virus entry is cooperatively mediated by multiple viral proteins and host cell components |
| Q34259469 | The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry |
| Q34039477 | The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein |
| Q35023719 | The structure of G4, the poxvirus disulfide oxidoreductase essential for virus maturation and infectivity |
| Q35963805 | The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins |
| Q42080789 | The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus |
| Q39950913 | The vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry |
| Q37791160 | Third-Generation Smallpox Vaccines: Challenges in the Absence of Clinical Smallpox |
| Q35665944 | Transcriptional repression and RNA silencing act synergistically to demonstrate the function of the eleventh component of the vaccinia virus entry-fusion complex |
| Q35947676 | Two distinct low-pH steps promote entry of vaccinia virus |
| Q35236032 | Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture |
| Q35826881 | Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH |
| Q92903685 | Vaccinia viral A26 protein is a fusion suppressor of mature virus and triggers membrane fusion through conformational change at low pH |
| Q24336532 | Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular cellular matrix laminin |
| Q36673363 | Vaccinia virus A56/K2 fusion regulatory protein interacts with the A16 and G9 subunits of the entry fusion complex |
| Q35101363 | Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein |
| Q35101454 | Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex |
| Q27488704 | Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans |
| Q35024254 | Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway |
| Q37066691 | Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies |
| Q36845831 | Vaccinia virus l1 protein is required for cell entry and membrane fusion |
| Q51740136 | Vaccinia virus phospholipase protein F13 promotes the rapid entry of extracellular virions into cells. |
| Q37238558 | Vaccinia virus strain differences in cell attachment and entry |
| Q39696174 | Vaccinia virus temperature-sensitive mutants in the A28 gene produce non-infectious virions that bind to cells but are defective in entry |
| Q60913456 | Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics |
| Q36842301 | Viral proteomics |
| Q27690636 | Viruses as nanomedicine for cancer |
| Q27303005 | Whole cell cryo-electron tomography reveals distinct disassembly intermediates of vaccinia virus |